Can-Fite BioPharma Files 6-K, Updates SEC Filings
Ticker: CANF · Form: 6-K · Filed: Sep 15, 2025 · CIK: 1536196
| Field | Detail |
|---|---|
| Company | Can-Fite Biopharma LTD. (CANF) |
| Form Type | 6-K |
| Filed Date | Sep 15, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, registration-update, compliance
Related Tickers: CFBI
TL;DR
CFBI files 6-K, updates S-8/F-3 filings. Standard procedure.
AI Summary
On September 15, 2025, Can-Fite BioPharma Ltd. filed a Form 6-K, incorporating by reference a press release. This filing is intended to update its Registration Statements on Form S-8 and Form F-3, ensuring that information within these statements remains current.
Why It Matters
This filing ensures that Can-Fite BioPharma's existing SEC registration statements are kept up-to-date, which is crucial for maintaining compliance and transparency with investors.
Risk Assessment
Risk Level: low — This is a routine filing to incorporate a press release into existing registration statements, not indicative of new material events.
Key Players & Entities
- Can-Fite BioPharma Ltd. (company) — Registrant
- September 15, 2025 (date) — Filing date
- Form 6-K (document) — Filing type
- Form S-8 (document) — Incorporated registration statement
- Form F-3 (document) — Incorporated registration statement
FAQ
What is the primary purpose of this Form 6-K filing by Can-Fite BioPharma Ltd.?
The primary purpose is to incorporate by reference a press release into the registrant's existing Registration Statements on Form S-8 and Form F-3, ensuring they remain current.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on September 15, 2025.
Which specific SEC registration statements are being updated by this filing?
The filing updates Registration Statements on Form S-8 (File Nos. 333-227753, 333-271384, and 333-278525) and Form F-3 (File Nos. 333-236064, 333-274316, 333-262055, 333-276000, and 333-281872).
Is Can-Fite BioPharma Ltd. required to file annual reports under Form 20-F or Form 40-F?
Can-Fite BioPharma Ltd. indicates it files annual reports under Form 20-F.
What is the principal executive office address for Can-Fite BioPharma Ltd.?
The principal executive offices are located at 26 Ben Gurion Street, Ramat Gan, 5257346, Israel.
Filing Stats: 268 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2025-09-15 07:10:48
Filing Documents
- ea0256784-6k_canfite.htm (6-K) — 12KB
- ea025678401ex99-1_canfite.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 96KB
- 0001213900-25-087400.txt ( ) — 157KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: September 15, 2025 By: /s/ Motti Farbstein Motti Farbstein Chief Executive Officer and Chief Financial Officer 3